Caprock Group LLC Buys New Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Caprock Group LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,155 shares of the specialty pharmaceutical company’s stock, valued at approximately $315,000.

A number of other hedge funds have also added to or reduced their stakes in COLL. Louisiana State Employees Retirement System grew its position in shares of Collegium Pharmaceutical by 1.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after acquiring an additional 300 shares during the period. SummerHaven Investment Management LLC grew its position in shares of Collegium Pharmaceutical by 1.3% in the 2nd quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock valued at $1,120,000 after acquiring an additional 452 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Collegium Pharmaceutical by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 535 shares during the period. CWM LLC grew its position in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares during the period.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $29.96 on Friday. Collegium Pharmaceutical, Inc. has a 52-week low of $25.16 and a 52-week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a 50-day moving average of $35.69 and a 200-day moving average of $34.77. The stock has a market cap of $966.21 million, a PE ratio of 12.91 and a beta of 0.95.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. The trade was a 15.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 13.81 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of analyst reports. Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright lifted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.